arrow
Y

Yukari Tsubata

gifu university
H指数:19
被引数:1,877

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Incidence and clinical features of venous thromboembolism in patients with lung cancer in Japan: results from the CS-Lung-003 prospective observational registry study

日本肺癌患者中静脉血栓栓塞症的发病率和临床特征:CS-Lung-003前瞻性观察性登记研究的结果

2025-11-010
OAAI
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis

Durvalumab在表皮生长因子受体突变型III期非小细胞肺癌患者接受同步化放疗后的应用:一项日本真实世界数据分析

2025-05-270
OA
Clinical outcomes of cancer-associated isolated distal deep vein thrombosis: a comparison between asymptomatic and symptomatic thrombosis-findings from the ONCO DVT Study
2025-02-010
OAAI
Utility of the modified Ottawa score for identification of more preferable candidates of extended anticoagulation therapy in cancer-associated isolated distal deep vein thrombosis: insight from the ONCO DVT Study
2024-12-010
PRE
Phase II trial of atezolizumab plus carboplatin and paclitaxel in patients with metastatic or recurrent thymic carcinoma: Marble study

II期临床试验:阿替利珠单抗联合卡铂和紫杉醇治疗转移性或复发性胸腺癌患者:Marble研究

2024-12-010
PRE
Lung immune prognostic index (LIPI) as a guide for addition of chemotherapy in immunotherapy in elderly patients (Pts) with non-small cell lung cancer (NSCLC): NEJ057

肺癌免疫预后指数(LIPI)作为指导老年非小细胞肺癌(NSCLC)患者(Pts)在免疫治疗中添加化疗的依据:NEJ057

2024-09-010
PRE
Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older
2024-06-173
OAAI
The impact of renal function on clinical outcomes of patients with cancer-associated isolated distal deep vein thrombosis: Insights from the ONCO DVT study
2024-03-012
PRE
Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial
2023-11-2116
PRE
Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101)
2023-11-012
PRE